Próspera ZEDE: The Biohacker City-State Rewriting the Rules

Photo: Photo by Sean Oulashin on Unsplash

Somewhere on a Caribbean island that most people associate with scuba diving and beach resorts, a small group of entrepreneurs, lawyers, and libertarian idealists has been building something the world has never quite seen before: a privately governed city-state with its own laws, its own courts, a flat income tax of roughly 1%, Bitcoin as an accepted currency — and, crucially for the biohacking world, a medical regulatory environment that operates entirely outside the reach of the US Food and Drug Administration.

It is called Próspera. And whether you view it as the future of human freedom or as a dangerous experiment in privatising governance, it is impossible to ignore what is happening there — especially if you care about the cutting edge of longevity science and biological self-optimization.

A Startup City Built From Scratch

The concept behind Próspera traces its intellectual lineage to the "charter cities" idea popularized by Nobel laureate economist Paul Romer: create a new jurisdiction with better institutions, attract people who want to live under those rules, and let competition between governance systems drive better outcomes. In practice, Próspera goes considerably further than Romer's academic framework.

Officially designated as a ZEDE — Zona de Empleo y Desarrollo Económico (Zone for Economic Development and Employment) — under a controversial 2013 Honduran law, Próspera has the legal authority to set its own regulations across an extraordinary range of domains: labor law, taxation, medical regulation, contract enforcement, and security. It operates not as a municipality of Honduras but as a parallel jurisdiction within Honduran territory, with its own arbitration courts and a private security force.

The zone currently occupies around 58 acres of land on Roatán, the largest of the Bay Islands off Honduras's Caribbean coast, directly next to the fishing community of Crawfish Rock. It is, by any conventional metric, tiny. But the regulatory surface area it commands is enormous — and that is precisely the point.

Where Is Próspera? Roatán, Honduras

Roatán sits in the Caribbean Sea roughly 65 kilometres off the northern coast of Honduras. The island is 77 kilometres long and no more than 8 kilometres wide at its broadest point. It is best known internationally as a diving destination — the Mesoamerican Barrier Reef System runs directly along its southern coast — but its political geography has become considerably more complex since Próspera established itself on its western end.

Access to Roatán is straightforward: Juan Manuel Gálvez International Airport (RTB) receives direct flights from Houston, Atlanta, and Miami. The island's tourist infrastructure is well-developed. Próspera itself sits in the less-touristed western section, where the contrast between the established fishing village of Crawfish Rock and the modernist architecture of the ZEDE's buildings is immediately visible.

Who Runs It — and From Where?

The entity behind Próspera is Honduras Próspera Inc., a private company formerly known as NeWay Capital, registered in Delaware — the US state famous for its corporate-friendly legal environment and minimal disclosure requirements. The irony of a libertarian city-state experiment being backed by a Delaware corporation is not lost on critics, though the legal advantages of Delaware incorporation are precisely what makes it the default choice for US-adjacent ventures of this type.

Among those reportedly connected to the project's funding are names from Silicon Valley's libertarian wing and the venture capital world. What is clear is that Próspera has attracted serious capital and serious legal talent. The ZEDE's governance documents — hundreds of pages of meticulously drafted regulatory frameworks — represent a significant investment in the idea that private governance can outperform state governance.

The Rules (or Lack Thereof)

Taxes, Courts, and Security

Próspera's tax structure is one of its central selling points. The zone levies an income tax of approximately 1% — compared to a top federal rate of 37% in the United States and 45% in Germany. There is no capital gains tax in the conventional sense. For entrepreneurs relocating from high-tax jurisdictions, the arithmetic is compelling.

Dispute resolution within Próspera bypasses Honduran national courts entirely. The zone operates the Próspera Arbitration Center, which applies a hybrid legal framework drawing on English common law, US contract law, and the zone's own regulatory code. This parallel judicial system is one of the most structurally radical elements of the experiment: in effect, a private court system operating on sovereign-adjacent territory.

Security is handled by a private contractor rather than the Honduran national police. For residents, this is presented as a feature — professional, accountable, well-equipped. For critics, it represents a troubling fragmentation of the state's monopoly on legitimate force.

Bitcoin as Official Currency

Próspera recognized Bitcoin as an official means of payment before El Salvador made it national legal tender in 2021. The zone's embrace of cryptocurrency is consistent with its broader ideological profile: distrust of central bank monetary policy, preference for hard decentralized assets, and appeal to the crypto-native entrepreneur class that overlaps significantly with the biohacking community. Bitcoin-denominated contracts, Bitcoin payroll, and Bitcoin-settled real estate transactions have all occurred within the ZEDE.

Why Biohackers Are the Core Constituency

For the global biohacking community, Próspera represents something that does not exist anywhere else at scale: a jurisdiction where the most advanced — and most legally fraught — interventions in human biology can be developed, tested, and administered with a fraction of the regulatory overhead required in the United States or the European Union.

This is not a minor footnote. The FDA's drug approval process is among the most rigorous in the world. A novel gene therapy targeting aging-related pathways can take 10–15 years and hundreds of millions of dollars to move from preclinical research to approved clinical use. The EMA in Europe operates similarly. For longevity researchers who believe — with scientific basis — that the intervention window narrows as they age, that timeline is not acceptable.

Biohackers have always operated at the frontier between self-experimentation and formal science. What makes Próspera different is that it has created a physical infrastructure for that frontier — not just online forums and DIY garage labs, but actual clinical facilities, practitioner networks, and a legal framework that permits what elsewhere requires years of regulatory navigation. The density of like-minded people and practitioners in the same physical space creates feedback loops that distributed online communities cannot replicate: when the person administering your gene therapy is presenting at a longevity conference two buildings away, the iteration speed between intervention and scientific discussion tightens considerably.

Gene Therapy Without FDA Oversight

The most consequential example of what Próspera makes possible is Minicircle, a biotech company that has conducted what it describes as the world's first commercial gene therapy trials on the island. Minicircle's protocol uses minicircle DNA vectors — circular DNA molecules stripped of bacterial sequences — to deliver follistatin genes to muscle tissue. Follistatin is a protein that inhibits myostatin, the body's natural muscle-growth suppressor. Elevated follistatin is associated with increased lean muscle mass and, in animal models, with extended lifespan markers.

A 2020 study in Nature Communications demonstrated the mechanistic basis for myostatin inhibition in extending healthspan in animal models, providing part of the scientific rationale for Minicircle's human protocol.^[PubMed] The participants who have traveled to Próspera to undergo this protocol are, in many cases, deeply informed members of the biohacking community — people who have read the underlying research, understand the risk profile, and have made a deliberate informed-consent decision to participate in an early-stage intervention unavailable at home. The intervention costs tens of thousands of dollars and requires health screening.

Peptides, NAD+, and the Full Biohacker Stack

Beyond gene therapy, Próspera has attracted practitioners working with interventions that occupy legal gray areas in their home jurisdictions. Peptide therapies — compounds like BPC-157, TB-500, and various growth hormone secretagogues — are widely discussed in biohacking circles globally, but their legal status varies dramatically by country. In Próspera, the regulatory framework is permissive enough that practitioners can administer and develop these protocols with considerably more freedom than in the US or EU.

The zone has also hosted work on NAD+ optimization protocols, plasmapheresis (plasma exchange that some longevity researchers believe may reduce aging biomarkers), and other interventions that are either unapproved, off-label, or simply unavailable at scale in regulated healthcare systems. For the serious biohacker, Próspera functions as a research and treatment hub — a place where the gap between what the science suggests might work and what the regulatory system permits has been deliberately compressed.

Inside Próspera — Video

This video is hosted by YouTube (Google LLC). Loading it connects to Google's servers and may set cookies. Google Privacy Policy

Accept & Load Video

Video: YouTube

The Controversy

Próspera is not without serious critics. The most fundamental objection comes from the Garífuna and Miskito indigenous communities whose ancestral territories include parts of Roatán. Many have argued that the ZEDE was established without meaningful consultation with the people most directly affected by the privatization of Honduran land and governance — a critique that sits uncomfortably against the zone's libertarian rhetoric about consent and voluntary participation.

The political situation has been turbulent. In 2022, Honduras's newly elected government under President Xiomara Castro moved to repeal the ZEDE law, declaring it unconstitutional. Próspera Inc. responded with a $10.7 billion ICSID arbitration claim under the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR), arguing that the repeal constituted an unlawful expropriation of its investment. The case remains unresolved and represents one of the largest investor-state dispute settlement claims ever filed against a developing country.

What This Means for the Future of Human Optimization

Próspera is best understood not as a blueprint for universal replication, but as a stress test of ideas the biohacking community has discussed for years: what happens when you remove regulatory constraints on human biological experimentation? Who benefits, who is harmed, and what does meaningful informed consent look like when people pay significant sums to participate in poorly-understood interventions?

The honest answer is that we do not yet know. The gene therapy trials conducted on the island have not generated peer-reviewed outcome data that would satisfy the standards of JAMA or Nature Medicine. Without controlled trials, without follow-up protocols, without adverse event reporting systems, the knowledge generated from individual interventions stays individual — it does not accumulate into the collective scientific record in a way that benefits anyone other than the participant.

At the same time, the argument that regulatory timelines cause measurable harm is not without merit. When a biological age reversal intervention that works in animal models takes 15 years to reach human clinical use, the people who might have benefited in that window are not an abstraction. The tension between caution and urgency is real, and Próspera has forced the biohacking community to confront it in ways that are no longer purely theoretical.

For biohackers, Próspera is not just a destination — it is a proof of concept. It demonstrates that regulatory arbitrage in biomedical research can be institutionalized, funded, and scaled. Whether that is a cause for optimism or alarm depends entirely on what happens next: whether the interventions conducted there generate data that feeds back into the scientific mainstream, or whether they remain an exclusive, expensive, and largely unaccountable frontier accessible only to those with the resources to get there.

Disclaimer: Die hier bereitgestellten Informationen dienen ausschließlich der Aufklärung, dem wissenschaftlichen Diskurs und der allgemeinen Information. Sie stellen keine medizinische Beratung, Diagnose oder Empfehlung dar. Viele der in der Biohacking-Szene diskutierten Substanzen und Methoden sind in der EU nicht für den menschlichen Konsum zugelassen, unterliegen dem Arzneimittelgesetz oder sind im Leistungssport als Doping eingestuft. Konsultiere vor jeglicher Anwendung immer einen qualifizierten Arzt.

Sources

1. Honduras ZEDE Law — Decreto No. 120-2013 (Congreso Nacional de Honduras): tsc.gob.hn
2. Minicircle gene therapy trials — minicircle.io
3. ICSID Arbitration — Honduras Próspera Inc. v. Republic of Honduras (Case No. ARB/23/31): icsid.worldbank.org
4. Lee S.J. et al. (2020). Myostatin inhibition and follistatin-mediated muscle hypertrophy. Nature Communications. pubmed.ncbi.nlm.nih.gov
5. Romer P. (2010). Technologies, Rules, and Progress: The Case for Charter Cities. Center for Global Development: cgdev.org
6. Harvard Health Publishing — Gene therapy: promise and current limitations: health.harvard.edu